Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma

Authors

Shadi Chamseddine
Betul Gok Yavuz
Yehia I Mohamed
Sunyoung S Lee
James C Yao
Zishuo Ian Hu
Michael LaPelusa
Lianchun Xiao
Ryan Sun
Jeffrey S Morris
Rikita I Hatia
Manal Hassan
Dan G Duda
Maria Diab
Amr Mohamed
Ahmed Nassar
Hesham M Amin
Ahmed Omar Kaseb

Publication Date

11-1-2024

Journal

Journal of Immunotherapy and Precision Oncology

Abstract

INTRODUCTION: Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data have suggested that galectin-3 plays a role in the development of hepatocellular carcinoma (HCC); however, its prognostic value has not been validated. The aim of our study was to evaluate the clinical and prognostic value of galectin-3 in patients with HCC.

METHODS: We prospectively enrolled and collected clinicopathologic data and serum samples from 767 patients with HCC between 2001 and 2014 at The University of Texas MD Anderson Cancer Center. Two hundred patients without HCC were also enrolled and had data collected. The Kaplan-Meier method was used to estimate overall survival (OS) distributions.

RESULTS: The median OS in this cohort was 14.2 months (95% CI, 12-16.1). At the time of analysis, the 1-year OS rate was 45% (95% CI, 0.4-0.51) among patients with high galectin-3 levels and 59% (95% CI, 0.54-0.63) among patients with low galectin-3 levels. OS was significantly inferior in patients with high galectin-3 levels than in patients with lower galectin-3 levels (median OS: 10.12 vs. 16.49 months;

CONCLUSION: Our study shows that serum galectin-3 level is a valid prognostic biomarker candidate.

Keywords

galectin-3, hepatocellular carcinoma, biomarker, overall survival, prognostic biomarkers

Comments

Associated Data

PMID: 39524465